Large new analyses presented at recent nephrology forums and published in JAMA report that sodium‑glucose cotransporter‑2 (SGLT2) inhibitors provide kidney protection across a broad spectrum of patients — independent of baseline glomerular filtration rate (GFR), albuminuria level, or diabetes status. The pooled evidence supports using SGLT2 inhibitors more routinely in chronic kidney disease and heart‑failure populations. The data set evaluated outcomes including preservation of eGFR, reductions in kidney‑failure events and hospitalizations for heart failure, and consistent effect sizes across albuminuria and GFR subgroups. Investigators emphasized that benefits extended to non‑diabetic CKD cohorts, underscoring a class effect beyond glycemic control. Clinicians and guideline committees are likely to weigh these findings when updating treatment algorithms; payers and sponsors will monitor population‑level implications for drug utilization and economic modeling.